• Skip to main content
  • Skip to header right navigation
  • Skip to site footer

Log in
  • Search
    • Search All SAGES Content
    • Search SAGES Guidelines
    • Search the Video Library
    • Search the Image Library
    • Search the Abstracts Archive
www.sages.org

SAGES

Reimagining surgical care for a healthier world

  • Home
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Awards
    • Who Is SAGES?
    • Leadership
    • Our Mission
    • Advocacy
    • Committees
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Committee Rosters
      • SAGES Past Presidents
  • Meetings
    • SAGES NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2026 Scientific Session Call for Abstracts
      • 2026 Emerging Technology Call for Abstracts
    • CME Claim Form
    • SAGES Past, Present, Future, and Related Meeting Information
    • SAGES Related Meetings & Events Calendar
  • Join SAGES!
    • Membership Application
    • Membership Benefits
    • Membership Types
      • Requirements and Applications for Active Membership in SAGES
      • Requirements and Applications for Affiliate Membership in SAGES
      • Requirements and Applications for Associate Active Membership in SAGES
      • Requirements and Applications for Candidate Membership in SAGES
      • Requirements and Applications for International Membership in SAGES
      • Requirements for Medical Student Membership
    • Member Spotlight
    • Give the Gift of SAGES Membership
  • Patients
    • Join the SAGES Patient Partner Network (PPN)
    • Patient Information Brochures
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find A SAGES Surgeon
  • Publications
    • Clinical / Practice / Training Guidelines, Statements, and Standards of Practice
    • Sustainability in Surgical Practice
    • SAGES Stories Podcast
    • Patient Information Brochures
    • Patient Information From SAGES
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • MesSAGES – The SAGES Newsletter
    • COVID-19 Archive
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • Avoid Opiates After Surgery
    • SAGES Subscription Catalog
    • SAGES TV: Home of SAGES Surgical Videos
    • The SAGES Safe Cholecystectomy Program
    • Masters Program
    • Resident and Fellow Opportunities
      • MIS Fellows Course
      • SAGES Robotics Residents and Fellows Courses
      • SAGES Free Resident Webinar Series
      • Fluorescence-Guided Surgery Course for Fellows
      • Fellows’ Career Development Course
    • SAGES S.M.A.R.T. Enhanced Recovery Program
    • SAGES @ Cine-Med Products
      • SAGES Top 21 Minimally Invasive Procedures Every Practicing Surgeon Should Know
      • SAGES Pearls Step-by-Step
      • SAGES Flexible Endoscopy 101
    • SAGES OR SAFETY Video Activity
  • Opportunities
    • Fellowship Recognition Opportunities
    • SAGES Advanced Flexible Endoscopy Area of Concentrated Training (ACT) SEAL
    • Multi-Society Foregut Fellowship Certification
    • Research Opportunities
    • FLS
    • FES
    • FUSE
    • Jobs Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • OWLS/FLS
You are here: Home / Abstracts / Immunologic Efficacy of E39 & E39’ Vaccination in a Phase I/IIa Trial in Ovarian & Endometrial Cancer Patients

Immunologic Efficacy of E39 & E39’ Vaccination in a Phase I/IIa Trial in Ovarian & Endometrial Cancer Patients

Jessica L Cindass, MD1, Annelies T Hickerson, MD1, Tommy A Brown II1, Kaitlin M Peace1, John W Myers III1, Timothy J Vreeland2, Diane F Hale1, Doreen O Jackson1, Julia M Greene3, John S Berry IV4, Guy T Clifton1, Garth S Herbert1, George E Peoples5. 1Brooke Army Medical Center, San Antonio, TX, 2University of Texas MD Anderson Cancer Center, Houston, TX, 3Tripler Army Medical Center, Honolulu, HI, 4Womack Army Medical Center, Fort Bragg, NC, 5Cancer Vaccine Development Program, San Antonio, TX

Background: The treatment options for cancer are ever-evolving and now include vaccines targeting tumor-specific immunogenic peptides to induce tumor cytolysis.  Folate binding protein (FBP) is a tumor-associated antigen (TAA) highly expressed in most endometrial and ovarian cancers, shielded from the normal immune system.  The most promising FBP peptides are E39 and an attenuated form, E39’ (aka J65).  In our most recent phase I/IIa trial we evaluated an E39+GM-CSF inoculation series at 3 doses (VG) vs controls (CG) as well as booster vaccination with E39 and or E39’ after the initial inoculation series.  Here we present the immunologic data from this phase I/IIa trial.

Methods: Patients with ovarian or endometrial cancer who were disease-free after standard of care therapy but at risk for recurrence were enrolled.  HLA-A2+ patients were enrolled in the VG, with the first 9 patients vaccinated in a 3+3 dose escalation of 100mcg, 500mcg, and 1000mcg, and the remaining patients receiving 1000mcg inoculations.  Vaccine was given every 3-4 weeks for a total of 6 doses.  Patients were then offered booster vaccination and randomized to receive E39 or E39’.  FBP expression level was measured on the resected disease.  Immunologic response was measured by delayed type hypersensitivity (DTH) and ELISPOT in the VG.

Results: A total of 29 patients were vaccinated, 9 patients received boosters with E39 and 9 with E39’.  Mean DTH prior to the initial dose of E39 was 5.74mm and after final dose was 10.33mm (p = 0.018).  Mean overall ELISPOT change over time through 18 months was +69.1 when compared to baseline (p=0.675).  At 18 months post vaccination, mean ELISPOT increased by +97.1 in 1000mcg vs -57.0 in in <1000mcg patients (p = 0.047).  At 18 months post vaccination, mean ELISPOT in patients with above average initial DTH increased by +255.33 from baseline, while those with below initial DTH showed a decrease from baseline of -0.75 (p = 0.004).  Immunological analyses were not significantly different between FBP high/low expression or E39 vs E39’ booster (p < 0.05).

Conclusions: E39 demonstrated significant overall immunogenicity on in vivo testing as measured by DTH. Ex vivo analysis (ELISPOT) suggests that E39 is more immunogenically efficacious in patients with baseline immunity to FBP (indicated by with > average initial DTH) and those who are optimally dosed (1000mcg).  FBP expression level and E39 vs E39’ use in booster inoculations did not significantly impact in vivo or ex vivo immunogenicity.


Presented at the SAGES 2017 Annual Meeting in Houston, TX.

Abstract ID: 94119

Program Number: MSS05

Presentation Session: Full-Day Military Surgical Symposium – Basic Science/Quality Improvement Presentations

Presentation Type: MSSPodium

40

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Mastodon (Opens in new window) Mastodon
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on Bluesky (Opens in new window) Bluesky

Related


sages_adbutler_leaderboard

Hours & Info

11300 West Olympic Blvd, Suite 600
Los Angeles, CA 90064

1-310-437-0544

[email protected]

Monday – Friday
8am to 5pm Pacific Time

Find Us Around the Web!

  • Bluesky
  • X
  • Instagram
  • Facebook
  • YouTube

Copyright © 2025 · SAGES · All Rights Reserved

Important Links

Healthy Sooner: Patient Information

SAGES Guidelines, Statements, & Standards of Practice

SAGES Manuals